Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634
2014
Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function. Blockade of the JAK-STAT pathway with a small molecule has been shown to provide therapeutic immunomodulation. Having identified JAK1 as a possible new target for arthritis at Galapagos, the compound library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by 3. Optimization within this chemical series led to identification of GLPG0634 (65, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn’s disease (CD).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
26
References
64
Citations
NaN
KQI